Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - Dainippon Sumitomo submitted an NDA to U.S. FDA for its atypical antipsychotic lurasidone for schizophrenia, and the company is hoping its newly acquired Sepracor sales force is up to the challenge in a crowded, but still fruitful, market

You may also be interested in...



Dainippon Sumitomo Pharma Advances Pipeline Despite Setbacks

TOKYO - Osaka-based Dainippon Sumitomo scored a few advances in its pipeline despite an earlier setback for its epilepsy medicine Stedesa (eslicarbazepine) when U.S. FDA asked for additional information last November and extended its PDUFA date 90 days to April 30, the company reported Feb. 3 when it announced earnings results for the April-December period. Stedesa is being developed by Dainippon's new subsidiary Sepracor

Dainippon Sumitomo Pharma Advances Pipeline Despite Setbacks

TOKYO - Osaka-based Dainippon Sumitomo scored a few advances in its pipeline despite an earlier setback for its epilepsy medicine Stedesa (eslicarbazepine) when U.S. FDA asked for additional information last November and extended its PDUFA date 90 days to April 30, the company reported Feb. 3 when it announced earnings results for the April-December period. Stedesa is being developed by Dainippon's new subsidiary Sepracor

Japanese Dainippon Sumitomo Pharma To Acquire Sepracor For $2.6 Billion

The share price of Sepracor surged by over 25 percent to a high of $22.80 before trading was halted mid-day on Sept. 2, amid speculation of an imminent takeover by Japan's Dainippon Sumitomo Pharma

Related Content

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel